



Genenta has been Awarded the **First Prize** at China-Italy Best Start Up Showcase & Entrepreneurship Competition 2018/2019 (**BSSEC**).
Genenta Presented at the **China-Italy Innovation Forum 2019** in Beijing (China)

November 27, 2019

FOSHAN & BEIJING (China) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they won the first prize at the BSSEC, China-Italy Best Start Up Showcase and Entrepreneurship Competition 2018/2019, on 25th of November in Foshan. The representative of Credit Business of China CICC Wealth Securities, Deepshire Capital, Haozheng Songyue Fund Management Company and the Vice-President of China Association of Inventions were part of the Chinese jury that chose between 12 different start-ups in the six vertical's project including the life science sector.

Genenta also presented at the China-Italy Innovation Forum in Beijing on 26th of November 2019, at the China National Convention Center. The program included an opening ceremony with the following Government Ministers:

- **Lorenzo Fioramonti**, Minister of Education, University and Research, Italian Representative
- **Wang Zhigang**, Minister of Science and Technology, Chinese Representative

Valentina Brambilla, Clinical Trial Assistant, will represent Genenta at the networking session of BSSEC in Beijing.

About Genenta Science

Genenta (www.genenta.com) has developed an ex-vivo gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to delivery immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Genenta's proprietary product is Temferon™.

The targeted expression of the immunomodulatory molecule in TEMs is achieved combining a transcriptional and post-transcriptional microRNA-mediated control. Thanks to these mechanisms, TEMs become capable of expressing the immunomodulatory molecule interferon-alpha (IFN- α) in the tumor microenvironment.

TEMs are endowed with a pro-angiogenic activity and are spontaneously and actively recruited by developing tumors to sustain their growth. Thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. In preclinical models, the local IFN- α release triggered both a direct (anti-angiogenic, pro-apoptotic) and an indirect anti-tumor effect (immune response).

In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ is not restricted to pre-selected tumor antigens nor type and may reach not only hematologic disorders but more importantly, also solid tumors. In addition, its immunomodulatory functions may trigger a long-lasting immune response towards multiple tumor antigens.

As a result, Temferon™ should be able to break the tumor immune tolerance by reprogramming the tumor immune microenvironment.

Temferon is under investigation in two Phase I/II clinical trials in early relapse Multiple Myeloma patients after front line therapy and newly diagnosed Glioblastoma Multiforme patients.

Genenta's headquarter is in Milan (Italy) with an office in Alexandria Center's LaunchLabs, New York (NY, USA). The Company is part of Assobiotech, Italia StartUp, and ELITE (London Stock Exchange Group).

Co-founders: Pierluigi Paracchi, Ospedale San Raffaele (OSR), Prof. Luigi Naldini (Director SR-TIGET, San Raffaele Telethon Institute for Gene Therapy), and Dr. Bernhard Gentner (Hematologist and Physician-Scientist at OSR and SR-TIGET). Dr. Carlo Russo, MD serves as CMO & Head of Development. Genenta raised more than €30M in three different rounds of financing.

Genenta Media/Investor Contact:

Valentina Brambilla, MSc
+39 388 789.15.41
valentina.brambilla@genenta.com

GENENTA SCIENCE Srl

Ospedale San Raffaele - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)
LaunchLabs - Alexandria Center, 14th Floor –
430 East 29th Street - New York, NY 10016 (USA)